1qmr: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1qmr.gif|left|200px]]
{{Seed}}
[[Image:1qmr.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1qmr|  PDB=1qmr  |  SCENE=  }}  
{{STRUCTURE_1qmr|  PDB=1qmr  |  SCENE=  }}  


'''BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G'''
===BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G===




==Overview==
<!--
Human type 1 immediate allergic response symptoms are caused by mediator release from basophils and mast cells. This event is triggered by allergens aggregating preformed IgE Abs bound to the high-affinity receptor (FcepsilonRI) on these cells. Thus, the allergen/IgE interaction is crucial for the cascade leading to the allergic and anaphylactic response. Two genetically engineered forms of the white birch pollen major allergen Bet v 1 with point mutations directed at molecular surfaces have been characterized. Four and nine point mutations led to a significant reduction of the binding to human serum IgE, suggesting a mutation-induced distortion of IgE-binding B cell epitopes. In addition, the mutated allergens showed a decrease in anaphylactic potential, because histamine release from human basophils was significantly reduced. Retained alpha-carbon backbone folding pattern of the mutated allergens was indicated by x-ray diffraction analysis and circular dichroism spectroscopy. The rBet v 1 mutants were able to induce proliferation of T cell lines derived from birch pollen allergic patients. The stimulation indices were similar to the indices of nonmutated rBet v 1 and natural Bet v 1 purified from birch pollen. The ability of anti-rBet v 1 mutant specific mouse IgG serum to block binding of human serum IgE to rBet v 1 demonstrates that the engineered rBet v 1 mutants are able to induce Abs reactive with nonmodified Bet v 1. rBet v 1 mutants may constitute vaccine candidates with improved efficacy/safety profiles for safer allergy vaccination.
The line below this paragraph, {{ABSTRACT_PUBMED_15470071}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 15470071 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_15470071}}


==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: Allergen]]
[[Category: Allergen]]
[[Category: Pathogenesis-related protein]]
[[Category: Pathogenesis-related protein]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 06:27:39 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 11:39:12 2008''

Revision as of 08:39, 28 July 2008

File:1qmr.png

Template:STRUCTURE 1qmr

BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G

Template:ABSTRACT PUBMED 15470071

About this Structure

1QMR is a Single protein structure of sequence from Betula pendula. Full crystallographic information is available from OCA.

Reference

Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses., Holm J, Gajhede M, Ferreras M, Henriksen A, Ipsen H, Larsen JN, Lund L, Jacobi H, Millner A, Wurtzen PA, Spangfort MD, J Immunol. 2004 Oct 15;173(8):5258-67. PMID:15470071

Page seeded by OCA on Mon Jul 28 11:39:12 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA